UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044620
Receipt number R000050054
Scientific Title An exploratory study investigating the effectiveness of the Quasi-particle accelerator (QPA) for fibromyalgia
Date of disclosure of the study information 2021/06/22
Last modified on 2024/03/29 15:56:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of the effectiveness of Quasi-particle accelerator (QPA) for fibromyalgia

Acronym

Examination of the effectiveness of Quasi-particle accelerator (QPA) for fibromyalgia

Scientific Title

An exploratory study investigating the effectiveness of the Quasi-particle accelerator (QPA) for fibromyalgia

Scientific Title:Acronym

An exploratory study investigating the effectiveness of the Quasi-particle accelerator (QPA) for fibromyalgia

Region

Japan


Condition

Condition

fibromyalgia

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Patients with fibromyalgia will be treated with QPA to evaluate efficacy (pain relief) and safety to determine if it could be a promising trial treatment for randomized controlled trials.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Total score of the Japanese version of the Revised Fibromyalgia Impact Questionnaire (JFIQR) before and 4 weeks after the start of QPA treatment

Key secondary outcomes

The changes in JFIQR domain (1), (2), (3) and each item before and 4 weeks after the start of QPA treatment


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Treatment with QPA (2.5 hours once, once a week, 5 times in total)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

Patients diagnosed with fibromyalgia according to the American College of Rheumatology (ACR) Fibromyalgia Preliminary Diagnostic Criteria (2010)
Prevalence period 6 months or more

Key exclusion criteria

Patients with implantable electronic devices (such as pacemakers)
Patients with serious heart disease, kidney disease, liver disease
Patients with arterial oxygen saturation <94% without oxygen
Patients with severe peripheral neuropathy
Persons who have lost temperature sensitivity
Patients who cannot express their intention
Patients with hypersensitivity, injury or lesions on the skin of the pad area (upper back and lower back)
Pregnancy

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Kenji
Middle name
Last name Tani

Organization

Tokushima University Hospital

Division name

Department of General Medicine and Primary Care

Zip code

770-8503

Address

3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan

TEL

088-633-9614

Email

taniken@tokushima-u.ac.jp


Public contact

Name of contact person

1st name Harutaka
Middle name
Last name Yamaguchi

Organization

Tokushima University Graduate School of Biomedical Sciences

Division name

Department of General Medicine

Zip code

770-8503

Address

3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan

TEL

088-633-9656

Homepage URL


Email

yharutaka@tokushima-u.ac.jp


Sponsor or person

Institute

Tokushima University

Institute

Department

Personal name



Funding Source

Organization

Asias Corp

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital

Address

2-50-1 Kuramoto-cho, Tokushima 770-8503, Japan

Tel

088-633-9294

Email

awachiken@tokushima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

徳島大学(徳島県)


Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

3

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2021 Year 05 Month 31 Day

Date of IRB

2021 Year 05 Month 31 Day

Anticipated trial start date

2021 Year 06 Month 22 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 06 Month 22 Day

Last modified on

2024 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050054


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name